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Abstract
Background—Exposure to bisphenol A (BPA), a chemical widely used in consumer products, 
has been associated with in vitro Cyp19 gene expression.
Objective—To evaluate an in vivo human model of Cyp19 gene expression in granulosa cells.
Study Design—A subset of an ongoing prospective cohort study of women undergoing in vitro 
fertilization (IVF) at Massachusetts General Hospital.
Methods—Mixed effect models were used to evaluate the association of urinary BPA 
concentrations with granulosa cell Cyp19 mRNA expression.
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Results—In 61 women undergoing 76 IVF cycles, adjusted changes in mean Cyp19 expression 
(β estimate (95% CI)) for quartiles 2,3 and 4 as compared to the lowest quartile were: −0.97 (− 
2.22, 0.28); −0.97 (−2.18, 0.24) and −0.38 (−1.58, 0.82).
Conclusions—An in vivo model for evaluation of Cyp19 gene expression was developed for use 
in epidemiologic studies. In this pilot study, we found no statistically significant linear association 
between urinary BPA concentrations and Cyp19 expression.
Keywords
bisphenol A; follicular fluid; ovary; granulosa cells; Cyp19; P450 aromatase; gene expression; 
fertility; human
Introduction
Bisphenol A (BPA) is a ubiquitous chemical widely used in the manufacture of a variety of 
consumer products, including polycarbonate plastics [1,2], epoxy resins, the lacquer lining 
of food and beverage cans [3,4], some dental sealants and composites [5,6], and thermal 
receipt paper [7,8]. This has led to widespread and continuous exposure of BPA in the 
general population. BPA was detected in over 90% of spot urine samples collected from a 
representative sample of the general U.S. population in the 2003–2004 National Health and 
Nutrition Examination Survey (NHANES) [9]. Detectable concentrations of BPA have also 
been measured in human follicular fluid [10].
BPA has been shown to act as an endocrine disrupting chemical [11, 12]. While its 
estrogenic properties were discovered almost 80 years ago [13], specific mechanisms by 
which BPA causes endocrine disruption remain uncertain. One plausible explanation 
includes altered expression of hormone-responsive genes. However, there is a lack of in vivo 
evidence for changes in sex hormone-responsive gene expression associated with human 
exposure to BPA.
Previously, we found significant negative associations between urinary BPA concentrations 
and serum peak estradiol (E2) and oocyte yield on the day of egg retrieval [14] in the 
context of an in vitro fertilization (IVF) study. These findings were replicated in another IVF 
cohort at the University of San Francisco (UCSF) affiliated fertility center in which serum 
unconjugated BPA concentrations were used as a biomarker of exposure [15]. These 
findings motivated us to explore the underlying pathway by which BPA reduces serum E2 
levels. While there is a paucity of human data, experimental animal and in vitro studies have 
consistently reported lower levels of Cyp19 messenger RNA (gene expression) with higher 
free BPA concentrations, ultimately leading to decreased P450 aromatase and ovarian E2 
synthesis [16 - 19]. Based on these findings, we explored whether urinary BPA 
concentrations were associated with decreased Cyp19 gene expression in our IVF cohort.
We designed an in vivo human model to examine the association between urinary BPA 
concentrations and granulosa cell gene expression of cytochrome P450, family 19, 
subfamily A, polypeptide 1(Cyp19A1, Cyp19) in women undergoing an oocyte retrieval 
procedure prior to IVF. Cyp19 encodes aromatase, a cytochrome P450 superfamily enzyme, 
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which converts androgens to estrogens and is highly expressed in granulosa cells. We 
hypothesized that the dose-dependent decreases in peak serum E2, previously observed in 
relation to urinary BPA concentrations in our larger prospective IVF cohort study cohort 
[14], are mediated by BPA-induced down-regulation of Cyp19 gene expression. A decrease 
in P450 aromatase synthesis would consequently result in decreased ovarian E2 synthesis by 
granulosa cells.
Methods
Study participants and data collection
The present analysis included women who had undergone IVF oocyte retrieval between 
October 2009 and June 2011 as part as part of their fertility treatment at the Massachusetts 
General Hospital (MGH) Fertility Center in Boston, MA USA. This sub-study was part of a 
larger prospective cohort study on the impact of environmental chemicals on fertility and 
pregnancy outcomes [20]. Follicular fluid samples were collected at the time of oocyte 
retrieval. Women between the ages of 18-45 years who used their own oocytes for IVF and 
who had BPA measurement available were eligible for the sub-study. Women were followed 
from study entry through each of their IVF cycles until either a live birth or the 
discontinuation of treatment at the MGH Fertility Center. The study was approved by the 
Institutional Review Boards of the MGH, Harvard School of Public Health (HSPH), and the 
Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
At recruitment, following informed consent, a nurse administered a brief questionnaire to 
collect data on demographics, medical history, and lifestyle. Clinical information was 
obtained from the electronic medical record and infertility diagnoses were assigned 
according to the Society for Assisted Reproductive Technology (SART) definitions.
Follicular fluid collection—On the day of oocyte retrieval, we collected aspirated 
follicular fluid from the consented study patient. Follicular fluid was aspirated at negative 
pressure (−130 mmHg) from the first 3 follicles. Three 1ml syringes were used to draw 
exactly 1ml of SAGE Quinn's Advantage Medium HEPES, which was added to each of the 
three collection tubes at the time of follicle aspiration. The embryologist then separated the 
oocytes from the follicular fluid aspirate and transferred the follicular fluid discard into three 
separate 15 ml BD polystyrene Falcon tubes, which we retrieved from the embryologist. The 
three Falcon tubes were kept on ice and then centrifuged at 1000 × g for 10 minutes until a 
granulosa cell pellet was formed. The supernatant was aliquoted into 2ml polypropylene 
cryovials and stored at −80°C, leaving 0.3 ml of supernatant in the Falcon tube, above the 
granulosa cell pellet. The Falcon tube was vortexed until the cells were in suspension. We 
prepared two cryostraws (IMV technologies unplugged mini straws) per aspirated follicle of 
100 μL of granulosa cell suspension in follicular fluid. The straws were heat-sealed and 
stored in liquid nitrogen in plastic canes. Three sets of field blanks for the follicular fluid 
aspiration procedure all tested negative for BPA contamination at the CDC. The granulosa 
cell samples were shipped on dry ice over night to the Flaws laboratory at the University of 
Illinois-Urbana, Champaign in two separate batches; the first in April 2011, and second in 
January 2012.
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Quantitative Polymerase Chain Reaction (qPCR) Analysis—Total RNA was 
extracted from follicles using the RNeasy Micro Kit (Qiagen, Inc., Valencia, CA) according 
to the manufacturer's protocol. Reverse transcriptase generation of complementary DNA 
(cDNA) was performed with 0.40 μg of total RNA using an iScript RT kit (Bio-Rad 
Laboratories, Inc., Hercules, CA). Real-time PCR (qPCR) was conducted using the CFX96 
Real-Time PCR Detection System (Bio-Rad Laboratories, Inc.) and accompanying software 
(CFX Manager Software) according to the manufacturer's instructions. The CFX96 
quantifies the amount of PCR product generated by measuring a dye (SYBR Green) that 
fluoresces when bound to double-stranded DNA. A standard curve was generated from five 
serial dilutions of one of the samples, thus allowing analysis of the amount of cDNA in the 
exponential phase. Specific qPCR primer sequences were used as follows: human β-actin 
(forward) 5′-TCA TGA AGT GTG ACG TTG ACA TCC GT-3′, (reverse) 5′-CCT AGA 
AGC ATT TGC GGT GCA CGA TG-3′; human Cyp19(forward) 5′-TGT GGA CGT GTT 
GAC CCT TCT-3′, (reverse) 5′- ACC ACG ATA GAT AGC ACT TTC GTC C-3′. β-actin 
was used as an internal standard. qPCR analysis was performed using 2 μl cDNA, forward 
and reverse primers (5 pmol) for β-actin and Cyp19, in conjunction with a SsoFast 
EvaGreen Supermix qPCR Kit (Bio-Rad Laboratories). An initial incubation of 95°C for 10 
min was followed by denaturing at 94°C for 10 s, annealing at 60°C for 10 s, and extension 
at 72°C for 10 s, for 40 cycles, followed by final extension at 72°C for 10 min. A melting 
curve was generated at 55–90°C to monitor the generation of a single product. The software 
also generated a standard curve. Final values of Cyp19 were calculated and expressed as the 
ratio normalized to β-actin, a housekeeping gene typically used for normalization of gene 
expression data in human studies [21, 22]. The assays were run in duplicate and the 
interassay variability for both β-actin and Cyp19 was low (0.18−0.33%).
Treatment Protocols and Clinical IVF Measures—Participants underwent one of 
three IVF treatment protocols, as described in detail previously [14]. Briefly, these included 
one of the following: 1) luteal phase gonadotropin releasing hormone (GnRH) agonist 
protocol using low, regular and high-dose leuprolide; 2) follicular phase GnRH-agonist/flare 
protocol; and 3) GnRH-antagonist protocol. Women who had responded poorly during past 
IVF cycles were the primary candidates for antagonist and flare protocols, with the flare 
protocol being indicated for women over age 40, whereas the antagonist protocol was 
assigned to women under age 40 with diminished ovarian reserve and poor ovarian 
response. Serum follicle stimulating hormone (FSH) was measured on cycle day 3, and 
measurements of serum E2 levels and details of oocyte retrieval have been previously 
described [14]. Peak serum E2 was measured from blood drawn approximately 36 hours 
prior to the patient's scheduled oocytes retrieval procedure.
Urine Sample Collection and Measurement of Urinary Bisphenol A 
Concentrations—Women provided up to two spot urine samples per IVF cycle, with the 
first one (not necessarily a fasting sample) collected between day 3 and day 9 of the 
gonadotropin phase, and the second, always a fasting sample, on the day of oocyte retrieval, 
typically prior to the procedure or administration of intravenous fluids. Urine was collected 
in a sterile clean polypropylene specimen cup. BPA concentrations were corrected for urine 
dilution by specific gravity (SG) using a conventional SG adjustment method [23]. SG was 
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measured at room temperature using a handheld refractometer (National Instrument 
Company, Inc., Baltimore, MD, USA), which was calibrated with deionized water before 
each measurement. The urine was divided into aliquots and frozen and stored at −80°C. 
Samples were shipped on dry ice overnight to the CDC where they were stored at or below 
−40°C until analysis for BPA concentrations.
The urinary concentrations of free and conjugated BPA species (total BPA) were measured 
using online solid phase extraction coupled to isotope dilution-high-performance liquid 
chromatography)-tandem mass spectrometry as described before [24]. First, 100 μL of urine 
was treated with β-glucuronidase/sulfatase (Helix pomatia, H1; Sigma Chemical Co, St. 
Louis, MO) to hydrolyze the BPA-conjugated species. We added a solution of 13C4-4- 
methylumbelliferone, 4-methylumbelliferyl sulfate, and 4-methylumbelliferyl glucuronide to 
all samples, and used it as a deconjugation standard. The 4-methylumbelliferone/ 13C4-4- 
methylumbelliferone peak area ratio was monitored to check the extent of the deconjugation 
reaction [24]. After hydrolysis, BPA was retained and concentrated on a C18 reversed-phase 
size-exclusion solid phase extraction column (Merck KGaA, Germany), separated from 
other urine matrix components using a pair of monolithic HPLC columns (Merck KGaA), 
and detected by negative ion-atmospheric pressure chemical ionization-MS/MS. The limit of 
detection (LOD) for BPA was 0.4 μg/L. In addition to study samples, each analytical run 
included low-concentration and high-concentration quality control materials, prepared with 
pooled human urine spiked with BPA, and reagent blanks to assure the accuracy and 
reliability of the data [24]. BPA concentrations below the LOD were assigned a value equal 
to the LOD divided by the square root of 2 [25] prior to adjustment for urine dilution by SG 
as described previously.
Statistical Analysis—Characteristics of the women and IVF cycle characteristics were 
summarized using means, standard deviations and percentages, as appropriate. The 
percentile distributions of the first and second spot urine samples (both unadjusted and SG 
adjusted) were summarized, as was the distribution of Cyp19 gene expression.
Mixed effect models were applied to evaluate the association between SG-adjusted urine 
BPA concentration (on the day of oocyte retrieval) and Cyp19 gene expression. We used the 
urine BPA concentration from the morning on the day of oocyte retrieval due to its close 
proximity in time to the collection of the granulosa cells whose gene expression would be 
expected to change within hours if there was a response to BPA exposure. BPA 
concentrations were adjusted for SG and then modeled in 2 ways: 1) as a continuous 
variable (on the natural log scale) and 2) as a categorical variable (in quartiles). We also 
used a similar modeling strategy to confirm the association previously observed between 
SG-adjusted urine BPA concentration and peak serum E2 within this subset. Although our 
sample size was limited, we also investigated whether adjustment for Cyp19 gene expression 
in this latter model had an impact on the association between BPA and E2. We used a 
compound symmetry correlation structure to account for correlation between repeated IVF 
cycles in the same woman, and adjusted for selected covariates which could be confounders.
To account for the decreased statistical power in this pilot study, we considered covariates as 
potential confounders if associated with the outcome of interest with p-value <0.3 in 
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univariate models. These covariates were chosen because of their clinical relevance to 
ovarian response and Cyp19 gene expression as evidenced in our earlier study [14]. 
Backward selection methods were used to identify variables for inclusion in the multivariate 
model. Covariates included IVF protocol type (flare/antagonist versus regular luteal phase 
protocol); day 3 serum FSH level (continuous measure); BMI (on a continuous scale); age 
and batch/shipment year (year 2012 versus year 2011). Characteristics represented by less 
than 5% of the cohort were not included as candidate predictors. Variables were retained in 
the final model if they had p-value ≤ 0.10. A test for trend was performed to determine if 
there was a linear dose-response relationship between quartiles of urinary BPA (coded 
ordinally as 1 to 4) and the log-transformed Cyp19 gene expression. All data analyses were 
performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
The 61 women included in our analyses were on average 35 years old at the time of 
recruitment to the study. These women underwent a total of 76 IVF cycles (48 women had a 
single IVF cycle, 11 women had two IVF cycles, and 2 women had 3 IVF cycles). Among 
these women, 88% were Caucasian and over 40% of the women were overweight or obese 
(BMI ≥ 25 kg/m2). Approximately one fifth had a primary SART diagnosis female factor, 
with 8% having a diagnosis of diminished ovarian reserve. Almost 40% of the 76 IVF cycles 
were assigned a low responder (flare or antagonist) protocol (Table I).
The non SG-adjusted BPA concentrations were comparable to those of the general U.S. 
population, with a median of 2.59 μg/L for the early cycle (day 3-9) and 1.97 μg/L for the 
later cycle (retrieval day urine) spot urine samples, compared to 1.73 μg/L for females in 
NHANES 2009-2010 [26]. The early cycle urine sample was not necessarily collected 
following fasting, whereas the retrieval day urine sample was always a fasting sample. This 
could possibly explain the higher median urinary BPA concentration in the early cycle than 
at retrieval day. The distribution of BPA concentrations was also comparable to those with 
measured BPA urinary concentrations in the IVF study overall [20]. Detectable 
concentrations of BPA were measured in 91% of spot urine urines. Cyp19 gene expression 
ranged from 0.006 to 19.6, with a median (interquartile range) of 0.43 (0.15-2.40) for the 76 
samples.
We observed no association between quartiles of urinary BPA concentration and log-
transformed Cyp19 gene expression, either with or without adjustment for BMI and the year 
each batch of granulosa cell samples were shipped to the Flaws laboratory for analysis 
(Table II). Two shipments of granulosa cell samples were sent to the laboratory; samples 
from 55 cycles were shipped in 2011 and 21 cycles were sent in 2012. Initially, qPCR was 
performed upon receipt of each shipment, therefore analyzed in two batches. Cycle 
characteristics (median peak E2, urine BPA, age and BMI) did not differ significantly 
between batches, with the exception of median Cyp19 gene expression, which was 
significantly higher for samples sent in 2011 (Wilcoxon test p-value<0.001) compared to 
samples sent in 2012. qPCR was rerun in the same assay for all 76 samples to assess quality 
control and a similar difference between 2011 and 2012 shipment batches was observed 
(Wilcoxon test p-value =0.001) (Supplementary figure I). The Spearman correlation for 
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Cyp19 gene expression between the first and repeat qPCR was high (r = 0.84, p-
value<0.0001). Results from the qPCR rerun of Cyp19 gene expression were used for 
univariate and multivariate analyses.
To confirm prior observations among the larger IVF cohort, we used mixed effects models 
to examine the association between SG-adjusted BPA (log transformed) from spot urine 
samples collected at the start of the treatment cycle and peak serum E2 measurements. After 
adjusting for age (≥ 37 years vs. < 37 years) and BMI (≥ 25 kg/m2 vs. < 25 kg/m2), an 
increase in SG-adjusted BPA urinary concentration from 1.43 μg/L (25th percentile) to 3.90 
μg/L (75th percentile) was associated with a decrease in peak serum E2 of 348 pg/ml (p-
value= 0.03). The decrease in peak serum E2 did not substantially change (342 pg/ml, p-
value=0.04) after adjusting for Cyp19 (natural log transformed). No significant associations 
were observed between Cyp19 and peak E2 (p-value=0.89).
Discussion
In this pilot study, we evaluated an in vivo human model designed to examine the 
association between exposure to BPA, estimated from urinary BPA concentrations, and 
ovarian granulosa cell Cyp19 gene expression. We made use of a larger ongoing prospective 
IVF cohort study for which granulosa cells had been extracted from follicular fluid aspirates 
(at oocyte retrieval) and appropriately stored in liquid nitrogen. Our study question was 
motivated by our previous study findings in the larger IVF cohort from which this sub-
sample was drawn, in which we found a negative association between urinary BPA 
concentrations and peak serum E2 [14, 20]. We were able to confirm these findings in this 
subgroup of 61 women undergoing 76 IVF cycles. Similar findings have also been 
replicated in a separate IVF cohort study [15]. We hypothesized that BPA-associated 
decreases in peak serum E2 may be mediated through the Cyp19 pathway in the ovarian 
granulosa cell. However, contrary to evidence from animal and in vitro studies [16, 18, 28], 
we did not observe a negative linear association between urinary BPA concentrations and 
Cyp19 gene expression. While there was no significant association between quartiles of SG-
adjusted urine BPA and Cyp19 expression, there was a suggestive nonmonotonic (U -
shaped) trend in both the unadjusted and adjusted models (Figure I). Larger studies are 
needed to further examine dose-response patterns. It is possible that the dose response 
association in vivo would not be linear because of the potential action of negative feedback 
loops at given concentrations of BPA, similar to the well-established action of endogenous 
E2 on FSH during the menstrual cycle. In this example, during the follicular phase, higher 
serum E2 concentrations inhibit hypothalamic production of GnRH through negative 
feedback, resulting in a decrease in FSH and E2 production. Conversely, in the luteal phase, 
low serum E2 concentrations trigger an increase in FSH production via a positive feedback 
loop. Evidence of non-monotonic dose response associations at environmentally relevant 
doses of BPA support the possibility that BPA may have different (non-monotonic) actions 
at different doses. [29 - 32]. Because this was a pilot study, sample size was limited and 
consequently, we might have lacked statistical power to detect small, but possibly clinically 
relevant changes, in Cyp19 expression, although very limited data are available on what 
would be considered a clinically relevant change in Cyp 19 expression.
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In our multivariable model (Table II), we adjusted for BMI and batch year. BMI is an 
important covariate because in premenopausal women, in addition to adipose tissue being a 
known precursor of E2 [33], it has also been associated with ovulatory infertility [34] and 
decreased sex hormone binding globulin (SHBG), which in turn results in decreased total 
serum E2 in both the follicular and luteal phase [35]. In our final batch-adjusted multivariate 
model (Table II), the association between BMI and Cyp19 gene expression (log 
transformed) was statistically significant (p-value=0.06) at the 0.10 significance level that 
we a priori established for this pilot study. Treatment protocol was not associated with 
Cyp19 gene expression and was therefore not included in our final multivariate model.
We found a batch year effect and noted a significant difference in Cyp19 gene expression 
depending on when the batch of samples was shipped to the laboratory (Supp figure I). This 
difference could potentially have been due to conditions during shipment (more RNA loss in 
the second shipment), although identical processing, storage and shipment protocols were 
followed [36]. Ideally, future studies should consider shipment of replicate samples in 
different batches for quality control. However, due to feasibility reasons, we were unable to 
conduct quality control experiments across shipments of samples. The RNA expression 
experiments were conducted twice. First, independently, i.e. as soon as each batch was 
received at the Flaws laboratory. Then, at a later date, the experiments were repeated on 
both batches in the same experiment. The correlation between the repeated measures was 
high (Spearman correlation coefficient = 0.84).
Our study was limited in sample size given that it was a pilot study. We had 80% power to 
detect differences in mean log transformed Cyp19 gene expression of 1.41 for women with 
high (above 1.97 μg/L) versus low (<1.97 μg/L) urine BPA concentrations at a 5% 
significance level. A post hoc power calculation (statistical program nQUery Advisor 7.0) 
was performed and in order to detect a difference in means, characterized by a variance of 
means of Cyp19 gene expression by urine BPA quartile. A sample size of 260 would be 
required at the 0.05 significance level, assuming the association found in this pilot study is a 
reflection of the true pattern of association. It is therefore difficult to draw definitive 
conclusions regarding the lack of association we observed between urine BPA concentration 
and Cyp19 expression. We cannot however dismiss the possibility that Cyp19 may not be on 
the causal pathway in humans. A recent animal study used an in vitro follicle culture system, 
administering BPA concentrations of 44 μM and 440 μM and found decreased E2 
production in mouse ovarian antral follicles, with corresponding decreased gene expression 
of steroid acute regulatory protein (Star) and cytochrome P450 side chain cleavage [37]. It is 
possible that this follicle culture system rather than a granulosa cell culture system better 
translates to our human in vivo model. In our follicular fluid aspirates, we were not able to 
examine Star gene expression because of the absence of theca cells in the aspirates. 
However, it is important to note that in humans BPA may affect different enzymes in the 
ovarian two-cell system (theca/granulosa cell) than those previously demonstrated in rats 
and mice.
Another consideration is that we do not know how well the BPA concentration in the urine 
reflects the BPA concentration at the relevant target, which is the follicle. Future 
experiments could involve measuring BPA concentrations in the follicular fluid [10, 37] and 
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explore associations with gene expression. It is possible that free BPA concentration at the 
target tissue is a more accurate measure of exposure than urine conjugated BPA 
concentration. In addition, since gene expression occurs within hours, it is possible that 
timing of our urine sample is not representative of the relevant biological window of 
exposure. We suggest replicating our Cyp19 analyses in a larger sample size in the future 
and also examining upstream genes in the granulosa cells (e.g., FSH receptors (FSHR), 
estrogen receptor beta (ESRβ), progesterone receptor (PGR) and others). This would provide 
important insights as to how BPA may potentially cause impaired ovarian steroidogenesis 
inwomen undergoing fertility treatment.
Conclusions
We evaluated an in vivo human model to study the underlying mechanism by which BPA 
decreases serum peak E2 in an IVF cohort. Although we observed no clear dose-response 
association between urinary SG-adjusted BPA and Cyp19 granulosa gene expression, our 
study does not rule out the possibility of a non-monotonic dose response association 
between quartiles of urinary BPA concentration and Cyp19 gene expression. Based on these 
preliminary data, a linear dose-response association was unlikely, but further studies are 
warranted to explore the relationships of Cyp19 gene expression with BPA exposure.
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• An in vivo human model looking at the underlying mechanism for BPA's action 
at the target tissue
• Translational pilot study on a subsample of a larger IVF cohort
• Possible non-monotonic dose-response association between BPA and Cyp 19 
gene expression in human ovarian granulosa cells
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Figure I. Quartiles of urinary BPA and Log CYP 19 gene expression
▲ Unadjusted
○ Adjusted for BMI and Batch/shipment (year 2012 versus year 2011)
Q1, lowest quartile (≤1.32 μg/L);
Q2, 2nd quartile (1.33-1.97 μg/L);
Q3, 3rd quartile Q3 (1.98-3.26 μg/L);
Q4, 4th quartile Q4 (≥3.27 μg/L)
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Table I
Subject demographics, infertility diagnoses and cycle characteristics among 61 women 
undergoing 76 IVF cycles
Characteristic Among 61 women N (%)
Age (years) Mean ± SD (range) 35.0 ± 4.1 (24 - 43)
 Age ≥ 37 (years) 22 (36%)
BMIa(Kg/m2) Mean ± SD (range) 25.1 ± 4.6 (19 -37)
 BMI ≥ 25 25 (42%)
Race
 Caucasian 54 (88%)
 other 7 (11%)
SART diagnosisb
 Female factor 13 (21%)
   Diminshed ovarian reserve 5 (8%)
   Ovulation disorders 6 (10%)
   Endometriosis 1 (2%)
   Tubal factor 1 (2%)
 Male infertility 25 (41%)
 Unexplained 21 (34%)
Cycle-Specific Characteristics Among 76 IVF Cycles, N (%)
IVF Protocolc
  Luteal Phase (LDLL/RDLL) 47 (63%)
  Low responder (Flare/ Antagonist) 28 (37%)
Mean ± SD (range)
Serum Day 3 FSH (IU/L)* 6.5 ± 2.2 (0.2-11.4)
Peak Serum Estradiol (pg/ml) 1980 ± 878 (603-4665)
Number of Oocytes retrieved 11 ± 6 (2-32)
Totals may not sum to 100% due to rounding
Abbreviations: BMI, body mass index: IVF, in vitro fertilization, LDLL,
Low-dose leuprolide lupron; RDLL, regular-dose leuprolide lupron;
FSH, follicle stimulating hormone;
a
BMI missing for 1 subject;
b
Primary diagnosis of infertility (2 missing values);
c
IVF protocol missing for 1 cycles.
*
missing day 3 FSH on 17 women, therefore this covariate was excluded from multivariate analyses
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